Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Prometic secures business deal with Chinese company
In the first order, the Chinese company will purchase Mimetic Ligand affinity adsorbent, developed and manufactured by the UK-based subsidiary of ProMetic, to manufacture a biosimilar product in
In the first order, the Chinese company will purchase Mimetic Ligand affinity adsorbent, developed and manufactured by the UK-based subsidiary of ProMetic, to manufacture a biosimilar product in
Most recently, Celniker worked as the president and CEO of Taligen Therapeutics. Before joining Taligen, Celniker was global head of biologics at Novartis, where she oversaw the biologics
The deal allows Mullis to become the chief scientific officer and Charles Roberts, CEO of Loxbridge, takes on the role of president of Altermune for the initial developmental
With this expansion, the company is now eligible to provide a range of microbiology testing services such as bacteriology, mycobacteriology and testing of microbioterrorism pathogens. The laboratory also
The work is being coordinated by AGTC under an agreement with researchers at Oregon Health & Science University Casey Eye Institute, David Wilson and The University of Florida,
AP-1531 is a potent and selective EP4 receptor antagonist that targets PGE2-EP4 binding which may treat migraines. In earlier studies, AP-1531 has demonstrated positive results in several disease
MWI distributes animal health products including feed additives, pharmaceuticals, vaccines, parasiticides, diagnostics, capital equipment, supplies, veterinary pet food and nutritional products. to veterinarians across the US and UK.
During the trial, Olesoxime is dosed at 330mg oral capsules once a day and riluzole is dosed in both arms at 50mg twice a day. In total, the
The funding was granted by CTI Life Sciences Fund (CTI), Advanced Biotechnologies Venture Fund (ABVF) and by several existing private shareholders. Zymeworks president and CEO said the investment
The FBP vaccine is a composition of E39 peptide combined with the immune adjuvant granulocyte macrophage colony stimulating factor (GM-CSF). RXi Pharma president and CEO Mark Ahn said